# A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

> **NCT01750697** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 25 (actual)

## Conditions studied

- Granulomatosis With Polyangiitis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01750697
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-23
- **Primary completion:** 2018-05-10
- **Final completion:** 2018-05-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01750697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01750697, "A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01750697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*